Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/194211 |
Resumo: | AIM: To investigate the survival rates after transarterial embolization (TAE). METHODS: One hundred third six hepatocellular carcinoma (HCC) patients [90 barcelona clinic liver cancer (BCLC) B] were submitted to TAE between August 2008 and December 2013 in a single center were retrospectively studied. TAE was performed via superselective catheterization followed by embolization with polyvinyl alcohol or microspheres. The date of the first embolization until death or the last follow-up date was used for the assessment of survival. The survival rates were calculated using the Kaplan-Meier method, and the groups were compared using the log-rank test. RESULTS: The overall mean survival was 35.8 mo (95%CI: 25.1-52.0). The survival rates of the BCLC A patients (33.7%) were 98.9%, 79.0% and 58.0% at 12, 24 and 36 mo, respectively, and the mean survival was 38.1 mo (95%CI: 27.5-52.0). The survival rates of the BCLC B patients (66.2%) were 89.0%, 69.0% and 49.5% at 12, 24 and 36 mo, respectively, and the mean survival was 29.0 mo (95%CI: 17.2-34). The survival rates according to the BCLC B sub-staging showed significant differences between the groups, with mean survival rates in the B1, B2, B3 and B4 groups of 33.5 mo (95%CI: 32.8-34.3), 28.6 mo (95%CI: 27.5-29.8), 19.0 mo (95%CI: 17.2-20.9) and 13 mo, respectively (P = 0.013). CONCLUSION: The BCLC sub-staging system could add additional prognosis information for postembolization survival rates in HCC patients. |
id |
UFRGS-2_53d557555f7ace474a20d9923318e6a1 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/194211 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Scaffaro, Leandro ArmaniStella, Steffan FrosiÁlvares-da-Silva, Mário ReisKruel, Cleber Dario Pinto2019-05-14T02:38:17Z20151948-5182http://hdl.handle.net/10183/194211000972976AIM: To investigate the survival rates after transarterial embolization (TAE). METHODS: One hundred third six hepatocellular carcinoma (HCC) patients [90 barcelona clinic liver cancer (BCLC) B] were submitted to TAE between August 2008 and December 2013 in a single center were retrospectively studied. TAE was performed via superselective catheterization followed by embolization with polyvinyl alcohol or microspheres. The date of the first embolization until death or the last follow-up date was used for the assessment of survival. The survival rates were calculated using the Kaplan-Meier method, and the groups were compared using the log-rank test. RESULTS: The overall mean survival was 35.8 mo (95%CI: 25.1-52.0). The survival rates of the BCLC A patients (33.7%) were 98.9%, 79.0% and 58.0% at 12, 24 and 36 mo, respectively, and the mean survival was 38.1 mo (95%CI: 27.5-52.0). The survival rates of the BCLC B patients (66.2%) were 89.0%, 69.0% and 49.5% at 12, 24 and 36 mo, respectively, and the mean survival was 29.0 mo (95%CI: 17.2-34). The survival rates according to the BCLC B sub-staging showed significant differences between the groups, with mean survival rates in the B1, B2, B3 and B4 groups of 33.5 mo (95%CI: 32.8-34.3), 28.6 mo (95%CI: 27.5-29.8), 19.0 mo (95%CI: 17.2-20.9) and 13 mo, respectively (P = 0.013). CONCLUSION: The BCLC sub-staging system could add additional prognosis information for postembolization survival rates in HCC patients.application/pdfengWorld journal of hepatology. Pleasanton, CA. Vol. 7, no. 3 (Mar. 2015), p. 628-632Neoplasias hepáticasCarcinomaEmbolização terapêuticaHepatocellular carcinomaSubclassificationTransarterial embolizationBarcelona clinic liver cancerSurvival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinomaEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT000972976.pdf.txt000972976.pdf.txtExtracted Texttext/plain22195http://www.lume.ufrgs.br/bitstream/10183/194211/2/000972976.pdf.txt8b57119265a4d0c7eed3e97432528f9aMD52ORIGINAL000972976.pdfTexto completo (inglês)application/pdf807981http://www.lume.ufrgs.br/bitstream/10183/194211/1/000972976.pdf0a260ff4ca9ee899ef9ddd4d02758347MD5110183/1942112023-10-26 03:40:00.591769oai:www.lume.ufrgs.br:10183/194211Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-10-26T06:40Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
title |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
spellingShingle |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma Scaffaro, Leandro Armani Neoplasias hepáticas Carcinoma Embolização terapêutica Hepatocellular carcinoma Subclassification Transarterial embolization Barcelona clinic liver cancer |
title_short |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
title_full |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
title_fullStr |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
title_full_unstemmed |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
title_sort |
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma |
author |
Scaffaro, Leandro Armani |
author_facet |
Scaffaro, Leandro Armani Stella, Steffan Frosi Álvares-da-Silva, Mário Reis Kruel, Cleber Dario Pinto |
author_role |
author |
author2 |
Stella, Steffan Frosi Álvares-da-Silva, Mário Reis Kruel, Cleber Dario Pinto |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Scaffaro, Leandro Armani Stella, Steffan Frosi Álvares-da-Silva, Mário Reis Kruel, Cleber Dario Pinto |
dc.subject.por.fl_str_mv |
Neoplasias hepáticas Carcinoma Embolização terapêutica |
topic |
Neoplasias hepáticas Carcinoma Embolização terapêutica Hepatocellular carcinoma Subclassification Transarterial embolization Barcelona clinic liver cancer |
dc.subject.eng.fl_str_mv |
Hepatocellular carcinoma Subclassification Transarterial embolization Barcelona clinic liver cancer |
description |
AIM: To investigate the survival rates after transarterial embolization (TAE). METHODS: One hundred third six hepatocellular carcinoma (HCC) patients [90 barcelona clinic liver cancer (BCLC) B] were submitted to TAE between August 2008 and December 2013 in a single center were retrospectively studied. TAE was performed via superselective catheterization followed by embolization with polyvinyl alcohol or microspheres. The date of the first embolization until death or the last follow-up date was used for the assessment of survival. The survival rates were calculated using the Kaplan-Meier method, and the groups were compared using the log-rank test. RESULTS: The overall mean survival was 35.8 mo (95%CI: 25.1-52.0). The survival rates of the BCLC A patients (33.7%) were 98.9%, 79.0% and 58.0% at 12, 24 and 36 mo, respectively, and the mean survival was 38.1 mo (95%CI: 27.5-52.0). The survival rates of the BCLC B patients (66.2%) were 89.0%, 69.0% and 49.5% at 12, 24 and 36 mo, respectively, and the mean survival was 29.0 mo (95%CI: 17.2-34). The survival rates according to the BCLC B sub-staging showed significant differences between the groups, with mean survival rates in the B1, B2, B3 and B4 groups of 33.5 mo (95%CI: 32.8-34.3), 28.6 mo (95%CI: 27.5-29.8), 19.0 mo (95%CI: 17.2-20.9) and 13 mo, respectively (P = 0.013). CONCLUSION: The BCLC sub-staging system could add additional prognosis information for postembolization survival rates in HCC patients. |
publishDate |
2015 |
dc.date.issued.fl_str_mv |
2015 |
dc.date.accessioned.fl_str_mv |
2019-05-14T02:38:17Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/194211 |
dc.identifier.issn.pt_BR.fl_str_mv |
1948-5182 |
dc.identifier.nrb.pt_BR.fl_str_mv |
000972976 |
identifier_str_mv |
1948-5182 000972976 |
url |
http://hdl.handle.net/10183/194211 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
World journal of hepatology. Pleasanton, CA. Vol. 7, no. 3 (Mar. 2015), p. 628-632 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/194211/2/000972976.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/194211/1/000972976.pdf |
bitstream.checksum.fl_str_mv |
8b57119265a4d0c7eed3e97432528f9a 0a260ff4ca9ee899ef9ddd4d02758347 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224965583798272 |